

**Appendix 1 Modified Jadad scale [posted as supplied by author]  
Methodological Quality Score**

*Adapted from Miller et al., 1995 and Jadad et al., 1996*

- MQ1 \_\_\_\_\_ Random assignment  
0 = Violated randomization and/or nonequivalence of comparison group was not addressed  
1 = Quasi-experimental design; arbitrary assignment; sequential; how:  
\_\_\_\_\_  
2 = Random assignment of groups of individuals (e.g., classrooms)  
3 = Matching individuals on some variable (e.g., SES, age), then random assignment  
4 = True randomization (i.e., participants had equal chance of receiving the intervention)
- MQ2 \_\_\_\_\_ Quality control  
0 = No standardization of treatment is specified  
1 = Treatment standardized by manual, specific training, content coding, etc
- MQ3 \_\_\_\_\_ Pretest post-test design? (0 = No, 1 = Yes)
- MQ4 \_\_\_\_\_ Follow-up rate (i.e., largest follow-up rate at any delayed post-test)  
2 = 85-100% completed    1 = 70 – 84% completed    0 = <70% completed
- MQ5 \_\_\_\_\_ Follow-up length (i.e., final assessment interval)  
2 = 6 months or longer    1 = 3 to 6 months    0 = less than 3 months
- MQ6 \_\_\_\_\_ Anonymity attempted (0 = No, 1 = Yes)
- MQ7 \_\_\_\_\_ Low reactivity of measure completion  
0 = no, intervention and measurement staff the same and/or face-to-face interviews were used  
1 = yes, used different personnel for intervention and measurement, and measurement technique not highly reactive (written rather than oral questions)
- MQ8 \_\_\_\_\_ Collateral verification of self-report  
0 = No collateral verification, not reported  
1 = At least some collaterals interviewed; if known, \_\_\_\_\_%
- MQ9 \_\_\_\_\_ Used objective measures  
0 = No objective measure used or unspecified (i.e., self-report only)  
1 = Objective measures (e.g., laboratory testing of STDs) used in more than 50% of the cases
- MQ10 \_\_\_\_\_ Withdrawal/Drop-outs (*\*\*This category applies to cases that withdrew after randomization*)  
0 = Not reported or all non-completers were excluded from analyses  
1 = Enumerated and/or compared with completed cases (e.g., intent-to-treat; baseline differences)
- MQ11 \_\_\_\_\_ Attrition (*\*\*This category applies to cases lost to follow-up after treatment*)  
0 = Cases lost to follow-up are not considered in outcome reporting  
1 = Enumerated *and* considered in outcome reporting (e.g., included in all possible analyses, imputed the mean for lost cases, compared with non-attrition cases at baseline)
- MQ12 \_\_\_\_\_ Independent/Double-blinding  
0 = Follow-up non-blind, unspecified, or questionnaire only  
1 = Follow-up assessments completed by independent interviewers blind to group assignment
- MQ13 \_\_\_\_\_ Analyses

0 = Descriptive analysis

1 = Appropriate inferential statistical analyses of group differences (e.g., comparing two groups using at least a *t* or *F* test but did not control for baseline and/or other characteristics)

2 = Controlled for baseline and/or other characteristics in appropriate statistical analyses of group differences (e.g., compared two groups using at least a *t* or *F* test)

MQ14 \_\_\_\_\_ Multisite

0 = Single site or comparison of sites offering different treatments

1 = Replication at  $\geq 2$  sites

MQ15 \_\_\_\_\_ Incentives Offered (0 = No, 1 = Yes)

MQ16 \_\_\_\_\_ Total Methodological Quality Score